Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Transplant Cell Ther. 2022 Dec 25;29(3):184.e1–184.e9. doi: 10.1016/j.jtct.2022.11.028

Figure 1:

Figure 1:

Kaplan-Meier estimates and cumulative incidence. (A) Overall survival: 2-year OS was 63% (95% CI 61–66%) and 73% (95%CI 67–79%) in the haploidentical and matched unrelated groups, P=0.007. (B) Progression free survival: 2-year PFS was 53% (95% CI 50–55%) and 63% (95%CI 57–69%) in the haploidentical and matched unrelated groups, P=0.004. (C) Non-relapse mortality: 2-year NRM was 21% (95% CI 19–23%) and 15% (95%CI 10–19%) in the haploidentical and matched unrelated groups, P=0.024. (D) Relapse: 2-year risk of lymphoma relapse was 27% (95% CI 25–29%) and 22% (95%CI 17–27%) in the haploidentical and matched unrelated groups, P=0.21.